Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 22, 2010, Pages 6592-6596

  Liu, Bin ^a   Lee, Younghee ^a   Zou, Jinming ^a   Petrassi, H Michael ^a   Joseph, Rhoda W ^a   Chao, Wenchun ^a   Michelotti, Enrique L ^a   Bukhtiyarova, Marina ^a   Springman, Eric B ^a   Dorsey, Bruce D ^a  

^a Ansaris   (United States)

Author keywords

NNRTIs; SAR

Indexed keywords

(3,4 DIHYDRO 2H BENZO[B][1,4]DIOXEPIN 7 YL)METHANAMINE; 4,6 DIAMINO 1,3,5 TRIAZIN 2 OL; EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; DRUG DISCOVERY; MODELS, MOLECULAR; RATS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

EID: 77958025074     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.09.034     Document Type: Article

References (15)

1. E. De Clercq Med. Chem. Res. 13 2004 439
2. J. Balzarini Curr. Top. Med. Chem. 4 2004 921
3. C. Sahlberg, and X. Zhou Anti-Infect. Agents Med. Chem. 7 2008 101
4. Z. Zhou, M. Madrid, J. Evanseck, and J. Madura J. Am. Chem. Soc. 127 2005 17253
5. J. Ren, and D.K. Stammers Virus Res. 134 2008 157
6. K. Andries, H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De Corte, J. Vingerhoets, R. Pauwels, and M.P. de Bethune Antimicrob. Agents Chemother. 48 2004 4680
7. D.W. Ludovici, R.W. Kavash, M.J. Kukla, C.Y. Ho, and H. Ye Bioorg. Med. Chem. Lett. 11 2001 2229
8. K. Le Van, C. Cauvin, S. de Walque, B. Georges, S. Boland, V. Martinelli, D. Demonté, F. Durant, L. Hevesi, and C. Van Lint J. Med. Chem. 52 2009 3636
9. 50's: Fusion inhibition >25 μM; Integrase >1000 μM; Protease >100 μM.
10. N. Baindur, N. Chadha, B. Brandt, D. Asgari, R. Patch, C. Schalk-HiHi, T. Carver, I. Petrounia, C. Baumann, H. Ott, C. Manthey, B. Springer, and M. Player J. Med. Chem. 48 2005 1717
11. B. Liu, K. Moffet, R. Joseph, and B. Dorsey Tetrahedron Lett. 46 2005 1779
12. N. Kaval, J. Van der Eycken, W. Dehaen, G. Strohmeier, C. Kappe, and E. Van der Eycken J. Comb. Chem. 5 2003 560
13. 50's: Fusion inhibition = 20 μM; Integrase >100 μM; Protease >100 μM.
14. Pharmacophore generation and searching, generation of ligand conformation and energy minimization were performed with MOE® (Chemical Computing Group).
15. K. Das, D. Clark Jr., P. Lewi, J. Heeres, M. De Jonge, L. Koymans, H. Vinkers, F. Daeyaert, D. Ludovici, M. Kukla, B. De Corte, R. Kavash, C. Ho, H. Ye, M. Lichtenstein, K. Andries, R. Pauwels, M. De Bethune, P. Boyer, P. Clark, S. Hughes, P. Janssen, and E. Arnold J. Med. Chem. 47 2004 2550